1467-C EFFICACY AND SAFETY OF COMBINATION TREATMENT OF TLR7 AGONIST TQA3334 AND ANTI-PD-L1 TQB2450 IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B PATIENTS: A PILOT RCT PHASE II STUDY (OCEAN cure05 STUDY) Ting Wu 1 , Di Wu 1 , Yuying Chen 1 , Da Huang 1 , Zhize Yuan 1 , Peng Wang 2 , Zhongnan Xu 3 , Shuna Wang 3 , Dandan Huo 3 , Weiming Yan 1 , Meifang Han 1 , Qin Ning 4 and Xiaojing Wang 5 , (1)State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China, (2)State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, (3)Chia Tai Tianqing Pharmaceutical Group Co., Ltd, (4)Institute and Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, (5)Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonostic Infectious Disease, Huazhong University of Science and Technology Background: Curing chronic hepatitis B (CHB) relies on the orchestration of innate and adaptive immunity in addition to profound viral replication suppression
and reverse mitochondrial dysfunction and inflammation (243)
This iron-overloaded and pro-oxidative milieu creates conditions conducive to ferroptosis in ectopic endometrial tissue in endometriosis
Moving to acellular formats, GelMA micro-spheres fabricated by microfluidics encapsulate MSC-derived exosomes pre-loaded with miR-21
Agents 51, 299303
